STOCK TITAN

Longeveron Inc. - $LGVN STOCK NEWS

Welcome to our dedicated page for Longeveron news (Ticker: $LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longeveron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longeveron's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
conferences
Longeveron Inc.

Nasdaq:LGVN

LGVN Rankings

LGVN Stock Data

6.98M
1.13M
6.71%
14.27%
1.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MIAMI

About LGVN

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome